In this study, we sought to gain new insights into sex-related differences in inflammatory arthritis. Using a murine model of synchronized CIA, we demonstrate that the clinical symptoms is more severe in CIA males with increased erosive disease markers in the joints and inflammatory cytokines in the serum, compared to females. We found that female CIA disease is skewed towards degranulating neutrophils and activated CD4+ T cells, with an increased inflammatory cytokine profile in the joints, compared to males. Similarly, in the cohort of RA patients, we found an increased abundance of inflammatory and neutrophil activation markers in female compared to male RA patients. Altogether, our data suggest that sex-related differences in immune responses are associated with the severity of inflammatory arthritis in CIA mice and in human RA patients.
Biological sex plays a key role in the prevalence, severity, and response to therapy in RA [5, 7, 33]. Although RA affects approximately 1% of the global population, females are impacted at a ratio of 3:1 compared to males [2, 4, 7, 33]. This sex disparity underscores the influence of hormonal, genetic, and immune-related factors in disease susceptibility [2, 4, 7, 33]. A majority of immunomodulatory-related genes are encoded on the X-chromosome, which further contributes to amplified immune responses in females in chronic diseases, increasing their predisposition to autoimmunity [3, 16, 34]. Additionally, females and males differ in their immune cell repertoires and elicit different immune responses during infection and chronic diseases. In general, females exhibit more robust adaptive immune responses compared to males, which may contribute to a differential regulation of inflammation in RA [16, 34].
The sex disparity in disease symptoms and severity of RA remains unelucidated. Therefore, in this study, we first aimed to characterize sex related differences in disease symptoms and severity using a CIA model. We found that male CIA mice exhibited more severe disease symptoms compared to female CIA mice and have increased levels of anti-collagen antibodies. An increase in clinical scores, circulating inflammatory cytokine/chemokine profiles in the serum, and joint degradation markers were male biased. Pro-inflammatory cytokines/chemokines such as 6Ckine/Exodus 2 (CCL21), MCP-1 (CCL2), IL-20, IL-16, IL-11, TNFα, IL-1α, RANTES (CCL5), MIP-1α (CCL3), and MIG (CXCL9) were significantly higher in circulation of male compared female CIA mice. These proinflammatory molecules can orchestrate the persistent immune dysregulation in RA leading to chronic inflammation and tissue damage. For example, cytokines such as TNF-α and IL-1α can amplify synovial inflammation, promoting fibroblast-like synoviocyte (FLS) activation and matrix degradation [35]. Similarly, cytokine IL-20 can induce osteoclastogenesis and bone erosion [36]. Chemokines such as 6Ckine/Exodus 2, MCP-1, RANTES, MIP-1α, and MIG and IL-16 can recruit and activate T cells and monocytes, fueling immune cell infiltration [37]. On the other hand, an elevated cytokine/chemokine profile in the joint tissues was female biased. Interestingly, we found that both proinflammatory cytokines and chemokines, such as IL-7, IL-2, IL-9, RANTES, MIP-3α, and IL-1α, as well as anti-inflammatory cytokines, such as IL-10 and IL-4, were higher in female compared to male CIA joints. Low levels of serum cytokines/chemokines and increased levels of anti-inflammatory cytokines in the joints of female CIA mice may explain their lower clinical scores compared to their male counterparts, despite increased proinflammatory cytokines in the female CIA mice joints. The clear male bias in disease severity observed in our study is in line with previous studies that demonstrated male mice have a higher susceptibility to develop arthritis and disease severity [38, 39], which, in part, could be attributed to the capacity of female sex hormones to suppress the development of CIA [38, 39]. Sex hormones such as estrogen, progesterone, and androgens can modulate the immune system, particularly in the context of RA. While we did not measure sex steroid levels in our study, several studies have demonstrated that estrogen and progesterone levels play key roles in defining the susceptibility and severity of RA disease [38–40]. The declining levels of estrogen and progesterone are linked to the increased risk of RA development [41, 42]. For example, decreased levels of estrogen and progesterone during menopause and postpartum increases the risk of RA, whereas increased estrogen and progesterone during pregnancy are protective against RA [41]. Studies using overiectomized DBA/1J mice and SKG mice reported increased inflammatory arthritis disease symptoms with increased levels of TNFα and IL-6 compared to sham operated mice [43, 44]. Interestingly, exogenous administration of estrogen and progesterone significantly reduced the disease severity and the serum levels of TNFα and IL-6. In addition, estrogen receptor alpha (ERα) was shown to mediate estrogen-driven suppression of disease symptoms in rat adjuvant arthritis [38, 39]. These studies highlight the critical role of sex hormones in arthritis development [43, 44] and provide an explanation for the male bias in disease severity observed in our study.
Although female CIA mice showed less disease severity compared to their male counterparts, we found that female CIA disease is skewed towards degranulating neutrophils and activated CD4+ T cells. It is well documented that RA onset and severity involves a dynamic interplay between innate and adaptive immune responses [10, 29]. Particularly, neutrophils and T cells play interdependent and critical roles driving both acute and chronic inflammatory processes that lead to joint damage [10, 29]. Neutrophils in the synovial fluid secrete proteases including NE, MMPs, and CRAMP that degrade cartilage and bone [10, 11, 45]. Further, secretion of NETs not only enhances inflammation, but exposes citrullinated proteins, key autoantigens implicated in the production of ACPAs, a classical feature of RA [10, 11, 45]. In parallel, CD4+ T cells, particularly Th1 and Th17 subsets, dominate the adaptive immune landscape in RA [10, 14, 46, 47]. CD4+ Th1 cells secrete IFN-γ, which activates macrophages to release pro-inflammatory cytokines such as TNFα and IL-1, while CD4+ Th17 cells produce IL-17, a potent mediator of neutrophil recruitment and osteoclast activation [10, 46, 48]. The interplay between neutrophils and CD4+ T cells is critical: neutrophil-derived NETs expose autoantigens which amplify T cell activation and proliferation, and T cell-mediated production of proinflammatory cytokines such as IL-17, enhances neutrophil infiltration and activation [10]. This self-sustaining loop underscores the complexity of RA pathogenesis. Our findings of CIA male-biased increased levels of CRAMP, and calprotectin in the joints, and IFNγ, IL-17 and IL-22 expressed by CD4+ T cells; and CIA female-biased increased CD4+ T cells and neutrophil activation markers such as NE, highlight the potential that different inflammatory and immunological mechanisms underlie disease severity differences in male versus female CIA mice.
In addition, in RA patients, despite higher disease activity in males (DAS28, p < 0.05), the female serum proteome profiles demonstrated enrichment of proteins in granulocyte and neutrophil activation determined by GO enrichment and GSEA. We speculate that, in females, neutrophil and CD4+ T cell activities switch to regulatory processes [10, 29, 49–51]. NE can tightly regulate immune NETosis, where the degradation of NETs can reduce autoantigen exposure and subsequent autoantibody production, potentially dampening the disease response [52, 53]. Additionally, NE may degrade specific pro-inflammatory cytokines/chemokines in a controlled manner, limiting synovial inflammation [49, 50]. NE can also remodel extracellular matrix components to release bioactive fragments with regulatory properties [49, 50]. Regulatory CD4+ T cells (Tregs) can control inflammation in RA by inhibiting the activation of Th1 and Th17 cells, thereby reducing IFN-γ and IL-17 production [9, 54]. Tregs can also induce the secretion of anti-inflammatory cytokines such as IL-10 and transforming growth factor-beta (TGF-β) in the synovium, reducing joint inflammation and damage. Future studies will investigate whether sex differences in diverse T cell subsets such as Tregs are associated with RA disease onset and severity. Altogether, our results suggest that neutrophil and CD4+ T cells may be programmed to regulate the disease in female mice and RA patients, in contrast to amplifying immune responses in males.
In summary, our study reveals novel sex-related differences in pro-inflammatory mediators and activities of neutrophils and CD4+ T cells, in CIA mice and in human RA patients. The findings of this study provide the foundation for future studies aimed at deciphering sex differences in molecular and immunological mechanisms underlying RA onset, which is significant to enhance our understanding of sex-specific RA risk factors and the development of intervention strategies personalized by sex.